Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: Strong Financial Position ... [Yahoo! Finance]
Pacira BioSciences, Inc. (PCRX)
Last pacira biosciences, inc. earnings: 2/20 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacira.com
Company Research
Source: Yahoo! Finance
iovera Sales: $5.7 million in Q3 2024, up from $5.3 million in 2023. Non-GAAP Gross Margin: 78% for Q3 2024. Non-GAAP R&D Expense: $17.3 million in Q3 2024, down from $18.6 million in 2023. Non-GAAP SG&A Expense: $65.0 million in Q3 2024, up from $58.9 million in 2023. Adjusted EBITDA: $54.7 million for Q3 2024. Goodwill Impairment Charge: $163.2 million non-cash, non-recurring charge. Cash and Investments: Over $450 million at the end of Q3 2024. Full-Year Revenue Guidance: $680 million to $705 million for 2024. Full-Year Non-GAAP Gross Margin Guidance: 74% to 76% for 2024. Full-Year Non-GAAP R&D Expense Guidance: $70 million to $80 million for 2024. Full-Year Non-GAAP SG&A Expense Guidance: $245 million to $265 million for 2024. Stock-Based Compensation Guidance: $50 million to $55 million for 2024. Warning! GuruFocus has detected 3 Warning Signs with PCRX. Release Date: November 06, 2024 For the complete transcript of the earnings call, please refer to
Show less
Read more
Impact Snapshot
Event Time:
PCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCRX alerts
High impacting Pacira BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
PCRX
News
- Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the FirmGlobeNewswire
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRXGlobeNewswire
- Pacira BioSciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRXPR Newswire
- PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewswire
- Contact Levi & Korsinsky by March 14, 2025 Deadline to Join Class Action Against Pacira BioSciences, Inc. (PCRX)GlobeNewswire
PCRX
Earnings
- 11/6/24 - Beat
PCRX
Sec Filings
- 2/4/25 - Form 4
- 2/4/25 - Form 4
- 2/4/25 - Form 4
- PCRX's page on the SEC website